Phase 1 N=39 Randomized Basic Science

A Study of Two Different Formulations of LY3502970 in Healthy Participants

Healthy

Bottom Line

View on ClinicalTrials.gov: NCT05341089 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2026

Primary outcome: Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2 — 86.5; 86.5 nanogram per milliliter (ng/mL)

Study Design & Population

Study type: Interventional
Phase: Phase 1
Interventions: LY3502970 (Drug)
Age: Adult, Older Adult · 21+ yrs
Sex: All
Sponsor: Eli Lilly and Company
Primary completion: Sep 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2	86.5; 86.5	—
PRIMARY PK: Area Under the Plasma Concentration-Time Curve (AUC) From 0 to 24 Hours (AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2	1260; 1240	—
PRIMARY PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Formulation 1 and Formulation 2	6.00; 6.00	—

Summary

The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream when administered as two different formulations in healthy participants. The study will also evaluate the safety and tolerability of LY3502970. The study will last up to 13 weeks excluding the screening period.

Eligibility Criteria

Inclusion Criteria

Are overtly healthy as determined by medical evaluation
Participants who have a hemoglobin level of at least 11.4 grams per deciliter (g/dL) for female participants and at least 12.5 g/dL for male participants
Participants with a body weight of at least 45 kilograms (kg) and body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m²)
Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential

Exclusion Criteria

Participants who have any abnormality in the 12-lead electrocardiogram (ECG) at screening
Participants who have an abnormal blood pressure, pulse rate, or both, which are deemed to be clinically significant by the investigator, at screening
Participants who have known allergies to LY3502970, related compounds, or any components of the formulation
Participants who have used or intend to use over-the-counter or prescription medication including herbal medications or traditional medications within 14 days prior to dosing
Participants who show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies, or both. A negative test within 6 months of screening would not need to be repeated.
Participants who show evidence of hepatitis C and/or positive hepatitis C antibody, or both. A negative test within 6 months of screening would not need to be repeated.
Participants who show evidence of hepatitis B, positive hepatitis B surface antigen, and/or positive hepatitis B core antibody, or all. A negative test within 6 months of screening would not need to be repeated.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05341089). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.